<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39412366</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-2092</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology</Title><ISOAbbreviation>Europace</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 ORF 3a-mediated currents are inhibited by antiarrhythmic drugs.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">euae252</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/europace/euae252</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been linked to cardiovascular complications, notably cardiac arrhythmias. The open reading frame (ORF) 3a of the coronavirus genome encodes for a transmembrane protein that can function as an ion channel. The aim of this study was to investigate the role of the SARS-CoV-2 ORF 3a protein in COVID-19-associated arrhythmias and its potential as a pharmacological target.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and cultured human fibroblasts were infected with SARS-CoV-2. Subsequent immunoblotting assays revealed the expression of ORF 3a protein in hiPSC-CM but not in fibroblasts. After intracytoplasmic injection of RNA encoding ORF 3a proteins into Xenopus laevis oocytes, macroscopic outward currents could be measured. While class I, II, and IV antiarrhythmic drugs showed minor effects on ORF 3a-mediated currents, a robust inhibition was detected after application of class III antiarrhythmics. The strongest effects were observed with dofetilide and amiodarone. Finally, molecular docking simulations and mutagenesis studies identified key amino acid residues involved in drug binding.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Class III antiarrhythmic drugs are potential inhibitors of ORF 3a-mediated currents, offering new options for the treatment of COVID-19-related cardiac complications.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wiedmann</LastName><ForeName>Felix</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-8168-0025</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HCR, Heidelberg Center for Heart Rhythm Disorders, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boondej</LastName><ForeName>Emika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanifer</LastName><ForeName>Megan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5606-1297</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, University of Florida, College of Medicine, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paasche</LastName><ForeName>Amelie</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6882-1428</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraft</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6764-2970</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HCR, Heidelberg Center for Heart Rhythm Disorders, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prüser</LastName><ForeName>Merten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeger</LastName><ForeName>Timon</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uhrig</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-8799-2249</Identifier><AffiliationInfo><Affiliation>Chemical Biology Core Facility, EMBL, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulant</LastName><ForeName>Steeve</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8614-4993</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, University of Florida, College of Medicine, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Constanze</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5897-237X</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HCR, Heidelberg Center for Heart Rhythm Disorders, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>German Cardiac Society</Agency><Country /></Grant><Grant><Agency>German Heart Foundation</Agency><Country /></Grant><Grant><Agency>German Foundation of Heart Research</Agency><Country /></Grant><Grant><Agency>German Centre for Cardiovascular Research</Agency><Country /></Grant><Grant><Agency>German Ministry of Education and Research</Agency><Country /></Grant><Grant><Agency>Else-Kröner Fresenius Foundation</Agency><Country /></Grant><Grant><GrantID>#422681845</GrantID><Agency>German Research Foundation</Agency><Country /></Grant><Grant><Agency>University of Florida</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Europace</MedlineTA><NlmUniqueID>100883649</NlmUniqueID><ISSNLinking>1099-5129</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086082">Viroporin Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C487105">3a protein, SARS-CoV</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1093/europace/euae254</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="Y">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="Y">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014982" MajorTopicYN="Y">Xenopus laevis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086082" MajorTopicYN="N">Viroporin Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3a protein</Keyword><Keyword MajorTopicYN="N">Antiarrhythmic drugs</Keyword><Keyword MajorTopicYN="N">Arrhythmias</Keyword><Keyword MajorTopicYN="N">COVID</Keyword></KeywordList><CoiStatement>Conflict of interest: none declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39412366</ArticleId><ArticleId IdType="pmc">PMC11481279</ArticleId><ArticleId IdType="doi">10.1093/europace/euae252</ArticleId><ArticleId IdType="pii">7823660</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Yet al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller IF, Becker AD, Grenfell BT, Metcalf CJE. Disease and healthcare burden of COVID-19 in the United States. Nat Med 2020;26:1212–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32546823</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanifer ML, Kee C, Cortese M, Zumaran CM, Triana S, Mukenhirn Met al. . Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells. Cell Rep 2020;32:107863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7303637</ArticleId><ArticleId IdType="pubmed">32610043</ArticleId></ArticleIdList></Reference><Reference><Citation>Triana S, Metz-Zumaran C, Ramirez C, Kee C, Doldan P, Shahraz Met al. . Single-cell analyses reveal SARS-CoV-2 interference with intrinsic immune response in the human gut. Mol Syst Biol 2021;17:e10232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8077299</ArticleId><ArticleId IdType="pubmed">33904651</ArticleId></ArticleIdList></Reference><Reference><Citation>Huseynov A, Akin I, Duerschmied D, Scharf RE. Cardiac arrhythmias in post-COVID syndrome: prevalence, pathology, diagnosis, and treatment. Viruses 2023;15:389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9959721</ArticleId><ArticleId IdType="pubmed">36851603</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TSet al. . Extrapulmonary manifestations of COVID-19. Nat Med 2020;26:1017–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulos PK, Freeman SV, Henry TD, Mahmud E, Messenger JC. Interaction of COVID-19 with common cardiovascular disorders. Circ Res 2023;132:1259–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10171313</ArticleId><ArticleId IdType="pubmed">37167359</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022;28:583–90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopinathannair R, Merchant FM, Lakkireddy DR, Etheridge SP, Feigofsky S, Han JKet al. . COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol 2020;59:329–36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7268965</ArticleId><ArticleId IdType="pubmed">32494896</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang Jet al. . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Musikantow DR, Turagam MK, Sartori S, Chu E, Kawamura I, Shivamurthy Pet al. . Atrial fibrillation in patients hospitalized with COVID-19: incidence, predictors, outcomes, and comparison to influenza. JACC Clin Electrophysiol 2021;7:1120–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7904279</ArticleId><ArticleId IdType="pubmed">33895107</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollborn J, Karamnov S, Fields KG, Yeh T, Muehlschlegel JD. COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients. Sci Rep 2022;12:12014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9281233</ArticleId><ArticleId IdType="pubmed">35835807</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewland TA, Marcus GM. SARS-CoV-2 infection and cardiac arrhythmias. Nat Cardiovasc Res 2022;1:1109–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9684811</ArticleId><ArticleId IdType="pubmed">36465413</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann Jet al. . Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265–73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Martin S, Shchendrygina A, Hoffmann J, Ka MM, Giokoglu Eet al. . Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat Med 2022;28:2117–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556300</ArticleId><ArticleId IdType="pubmed">36064600</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MY, Xiao FP, Kuai L, Zhou HB, Jia ZQ, Liu Met al. . Outcomes of atrial fibrillation in patients with COVID-19 pneumonia: a systematic review and meta-analysis. Am J Emerg Med 2021;50:661–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8483996</ArticleId><ArticleId IdType="pubmed">34879483</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinoni EG, Mennuni M, Rognoni A, Grisafi L, Colombo C, Lio Vet al. . Contribution of atrial fibrillation to in-hospital mortality in patients with COVID-19. Circ Arrhythm Electrophysiol 2021;14:e009375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7892203</ArticleId><ArticleId IdType="pubmed">33591815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mountantonakis SE, Saleh M, Fishbein J, Gandomi A, Lesser M, Chelico Jet al. . Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Heart Rhythm 2021;18:501–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7825902</ArticleId><ArticleId IdType="pubmed">33493650</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RCet al. . Attributes and predictors of long COVID. Nat Med 2021;27:626–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu Xet al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen Set al. . SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–280.e278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern DM, Sorum B, Mali SS, Hoel CM, Sridharan S, Remis JPet al. . Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs. Nat Struct Mol Biol 2021;28:573–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8772433</ArticleId><ArticleId IdType="pubmed">34158638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W, Zheng BJ, Xu K, Schwarz W, Du L, Wong CKet al. . Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release. Proc Natl Acad Sci U S A 2006;103:12540–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1567914</ArticleId><ArticleId IdType="pubmed">16894145</ArticleId></ArticleIdList></Reference><Reference><Citation>Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert ADet al. . Chemically defined generation of human cardiomyocytes. Nat Methods 2014;11:855–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169698</ArticleId><ArticleId IdType="pubmed">24930130</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian X, Zhang J, Azarin SM, Zhu K, Hazeltine LB, Bao Xet al. . Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc 2013;8:162–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612968</ArticleId><ArticleId IdType="pubmed">23257984</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Wiedmann F, Voigt N, Zhou XB, Heijman J, Lang Set al. . Upregulation of K2P3.1K+ current causes action potential shortening in patients with chronic atrial fibrillation. Circulation 2015;132:82–92.</Citation><ArticleIdList><ArticleId IdType="pubmed">25951834</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Wiedmann F, Zhou XB, Heijman J, Voigt N, Ratte Aet al. . Inverse remodelling of K2P3.1K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. Eur Heart J 2017;38:1764–74.</Citation><ArticleIdList><ArticleId IdType="pubmed">28057773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedmann F, Kiper AK, Bedoya M, Ratte A, Rinné S, Kraft Met al. . Identification of the A293 (AVE1231) binding site in the cardiac two-pore-domain potassium channel TASK-1: a common low affinity antiarrhythmic drug binding site. Cell Physiol Biochem 2019;52:1223–35.</Citation><ArticleIdList><ArticleId IdType="pubmed">31001961</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedmann F, Beyersdorf C, Zhou XB, Kraft M, Paasche A, Jávorszky Net al. . Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Cardiovasc Res 2021;117:1790–801.</Citation><ArticleIdList><ArticleId IdType="pubmed">34028533</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards S, Small JD, Geratz JD, Alexander LK, Baric RS. An experimental model for myocarditis and congestive heart failure after rabbit coronavirus infection. J Infect Dis 1992;165:134–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202395</ArticleId><ArticleId IdType="pubmed">1309370</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey AL, Dmytrenko O, Greenberg L, Bredemeyer AL, Ma P, Liu Jet al. . SARS-CoV-2 infects human engineered heart tissues and models COVID-19 myocarditis. JACC Basic Transl Sci 2021;6:331–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7909907</ArticleId><ArticleId IdType="pubmed">33681537</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso C, Leone O, Rizzo S, De Gaspari M, van der Wal AC, Aubry MCet al. . Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J 2020;41:3827–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543528</ArticleId><ArticleId IdType="pubmed">32968776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV 3rdet al. . COVID-19 and cardiovascular disease: from bench to bedside. Circ Res 2021;128:1214–36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8048382</ArticleId><ArticleId IdType="pubmed">33856918</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Zhao P, Tang D, Zhu T, Han R, Zhan Cet al. . Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging. JACC Cardiovasc Imaging 2020;13:2330–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7214335</ArticleId><ArticleId IdType="pubmed">32763118</ArticleId></ArticleIdList></Reference><Reference><Citation>Polina I, Guo Y, Jhun BS, Tolkacheva E, O-Uchi J. Expression of SARS-CoV-2 viroporins triggers cardiac arrhythmia. FASEB J 2021;35. doi:10.1096/fasebj.2021.35.S1.04486</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.2021.35.S1.04486</ArticleId></ArticleIdList></Reference><Reference><Citation>Polina IA, Guo Y, Cypress MW, Tolkacheva EG, Sook Jhun B, O-Uchi J. Expression of SARS-CoV-2-ORF3a protein induces cardiomyocyte damage. Biophys J 2022;121:237a.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz S, Sauter D, Lu W, Wang K, Sun B, Efferth Tet al. . Coronaviral ion channels as target for Chinese herbal medicine. Onco Therapeutics 2012;3:1–13.</Citation></Reference><Reference><Citation>Schwarz S, Sauter D, Wang K, Zhang R, Sun B, Karioti Aet al. . Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus. Planta Med 2014;80:177–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7171712</ArticleId><ArticleId IdType="pubmed">24458263</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz S, Wang K, Yu W, Sun B, Schwarz W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Res 2011;90:64–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114100</ArticleId><ArticleId IdType="pubmed">21356245</ArticleId></ArticleIdList></Reference><Reference><Citation>Toft-Bertelsen TL, Jeppesen MG, Tzortzini E, Xue K, Giller K, Becker Set al. . Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2. Commun Biol 2021;4:1347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8636635</ArticleId><ArticleId IdType="pubmed">34853399</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan CM, Tsoi H, Chan WM, Zhai S, Wong CO, Yao Xet al. . The ion channel activity of the SARS-coronavirus 3a protein is linked to its pro-apoptotic function. Int J Biochem Cell Biol 2009;41:2232–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108357</ArticleId><ArticleId IdType="pubmed">19398035</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien T-H, Chiang Y-L, Chen C-P, Henklein P, Hänel K, Hwang I-Set al. . Assembling an ion channel: ORF 3a from SARS-CoV. Biopolymers 2013;99:628–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161858</ArticleId><ArticleId IdType="pubmed">23483519</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller AN, Houlihan PR, Matamala E, Cabezas-Bratesco D, Lee GY, Cristofori-Armstrong Bet al. . The SARS-CoV-2 accessory protein ORF3a is not an ion channel, but does interact with trafficking proteins. Elife 2023;12:e84477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9910834</ArticleId><ArticleId IdType="pubmed">36695574</ArticleId></ArticleIdList></Reference><Reference><Citation>McClenaghan C, Hanson A, Lee SJ, Nichols CG. Coronavirus proteins as ion channels: current and potential research. Front Immunol 2020;11:573339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7586316</ArticleId><ArticleId IdType="pubmed">33154751</ArticleId></ArticleIdList></Reference><Reference><Citation>Issa E, Merhi G, Panossian B, Salloum T, Tokajian S. SARS-CoV-2 and ORF3a: nonsynonymous mutations, functional domains, and viral pathogenesis. mSystems 2020;5:e00266-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205519</ArticleId><ArticleId IdType="pubmed">32371472</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffajee CI, Love JC, Alpert JS, Asdourian GK, Sloan KC. Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience. Am Heart J 1983;106:935–43.</Citation><ArticleIdList><ArticleId IdType="pubmed">6613840</ArticleId></ArticleIdList></Reference><Reference><Citation>Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984;9:136–56.</Citation><ArticleIdList><ArticleId IdType="pubmed">6370540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gierten J, Ficker E, Bloehs R, Schweizer PA, Zitron E, Scholz Eet al. . The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone. Naunyn Schmiedebergs Arch Pharmacol 2010;381:261–70.</Citation><ArticleIdList><ArticleId IdType="pubmed">19777211</ArticleId></ArticleIdList></Reference><Reference><Citation>Veronese ME, McLean S, Hendriks R. Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. Br J Clin Pharmacol 1988;26:721–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1386587</ArticleId><ArticleId IdType="pubmed">3242577</ArticleId></ArticleIdList></Reference><Reference><Citation>Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe Set al. . Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32–45.</Citation><ArticleIdList><ArticleId IdType="pubmed">12667944</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Wiedmann F, Schweizer PA, Becker R, Katus HA, Thomas D. Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels. Naunyn Schmiedebergs Arch Pharmacol 2012;385:1003–16.</Citation><ArticleIdList><ArticleId IdType="pubmed">22790794</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Wiedmann F, Schweizer PA, Becker R, Katus HA, Thomas D. Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K+ (K2P) channels. Eur J Pharmacol 2013;721:237–48.</Citation><ArticleIdList><ArticleId IdType="pubmed">24070813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedmann F, Frey N, Schmidt C. Two-pore-domain potassium (K2P-) channels: cardiac expression patterns and disease-specific remodelling processes. Cells 2021;10:2914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8616229</ArticleId><ArticleId IdType="pubmed">34831137</ArticleId></ArticleIdList></Reference><Reference><Citation>Castaño-Rodriguez C, Honrubia JM, Gutiérrez-Álvarez J, DeDiego ML, Nieto-Torres JL, Jimenez-Guardeño JMet al. . Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis. mBio 2018;9:e02325-17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964350</ArticleId><ArticleId IdType="pubmed">29789363</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvas JA, Vasquez DM, Park JG, Chiem K, Allué-Guardia A, Garcia-Vilanova Aet al. . Contribution of SARS-CoV-2 accessory proteins to viral pathogenicity in K18 human ACE2 transgenic mice. J Virol 2021;95:e0040221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354228</ArticleId><ArticleId IdType="pubmed">34133899</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus OB. HTS assays for developing the molecular pharmacology of ion channels. Curr Opin Pharmacol 2014;15:91–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24556186</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>